Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;14(7):1729-1738.
doi: 10.1007/s13555-024-01193-1. Epub 2024 Jun 14.

Biomarkers in Atopic Dermatitis

Florence Libon  1 , Juliette Caron  2 , Arjen F Nikkels  3
Affiliations
Review

Biomarkers in Atopic Dermatitis

Florence Libon et al. Dermatol Ther (Heidelb). 2024 Jul.

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin condition. The pathogenesis involves genetic, environmental, and immunological factors as well as a barrier dysfunction of the epidermis. Biomarkers may play a significant role in diagnosis, severity assessment, and treatment monitoring of AD. They are categorizable into diagnostic and prognostic as well as severity and stratification biomarkers, offering the potential for a more personalized treatment approach. Although there have been tremendous therapeutic advancements with interleukin (IL) antagonists and Janus kinase (JAK) inhibitors, the domain of biomarkers still requires further research to clarify their place in the diagnosis and prognosis of AD to unravel a better scientific basis for personalized medical care for patients with AD. This article reviews the various biomarkers in relation to the different AD phenotypes and endotypes.

Keywords: Atopic dermatitis; Biomarkers; Diagnosis; Endotype; Personalized treatment; Prognosis.

PubMed Disclaimer

Conflict of interest statement

None of the authors (Florence Libon, Juliette Caron) have conflicting interests. Arjen F. Nikkels is an Editorial Board member of Dermatology and Therapy. Arjen F. Nikkels was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

Similar articles

See all similar articles

Cited by

References

    1. Bakker D, de Bruin-Weller M, Drylewicz J, et al. Biomarkers in atopic dermatitis. J Allergy Clin Immunol. 2023;151:1163–8. 10.1016/j.jaci.2022.10.007. 10.1016/j.jaci.2022.10.007 - DOI - PubMed
    1. Ziehfreund S, Tizek L, Hangel N, et al. Requirements and expectations of high-quality biomarkers for atopic dermatitis and psoriasis in 2021-a two-round Delphi survey among international experts. J Eur Acad Dermatol Venereol. 2022;36:1467–76. 10.1111/jdv.18422. 10.1111/jdv.18422 - DOI - PubMed
    1. David E, Ungar B, Renert-Yuval Y, Facheris P, del Duca E, Guttman-Yassky E. The evolving landscape of biologic therapies for atopic dermatitis: present and future perspective. Clin Exp Allergy. 2023;53:156–72. 10.1111/cea.14034. 10.1111/cea.14034 - DOI - PubMed
    1. Mesjasz A, Kołkowski K, Wollenberg A, Trzeciak M. How to understand personalized medicine in atopic dermatitis nowadays? Int J Mol Sci. 2023;24:7557. 10.3390/ijms24087557. 10.3390/ijms24087557 - DOI - PMC - PubMed
    1. Mastraftsi S, Vrioni G, Bakakis M. Atopic dermatitis: striving for reliable biomarkers. Clin Med. 2022;11:4639. 10.3390/jcm11204639.10.3390/jcm11204639 - DOI - PMC - PubMed

LinkOut - more resources